News

In a small study, the newly FDA approved antifungal demonstrated “clinical activity” against the emerging pathogen.

Use of remdesivir for COVID-19 was associated with longer hospital stays but was not associated with improved mortality, a recent study of 2344 patients at 123 VA hospitals found.

This approval of the non-live, recombinant sub-unit adjuvanted vaccine, Shingrix, is for the prevention of shingles in adults aged 18 years and older with increased risk of immunodeficiency or immunosuppression.

Modeling showed 1 in 4 infected people pass the infection to a family member.

Pfizer and Moderna will include children aged 5-11 years old in ongoing trials to speak toward risk of rare adverse events observed in other young recipients.

The statement includes over 50 societies and organizations, representing millions of workers.

The company will review the CRL and request a Type A meeting in the coming weeks.

This therapy becomes the first single-dose infusion to treat acute bacterial skin and skin structure infections (ABSSSI) in pediatric patients from birth.

Communities experiencing such health inequity and disparities are more likely to have mistrust in systems that have continuously failed them. Understanding the perspectives of those disproportionately affected is critical to not only address them, but also work to correct and prevent these disparities moving forward.

An emergency department in Canada saw a steep drop in emergency department visits and a spike in the proportion of serious bacterial infections among newborns and young infants during the first year of the pandemic, a new study found.

With millions of Americans affected by sexually transmitted infections (STI) an emphasis on prevention and control strategies was included in the recommendations.

Not much is known about the relationship between the expression and activity of SPM pathways and COVID-19 disease severity.

The clusters were identified in Washington, DC, and the Dallas area.

The lineage C.37, (Lambda variant), was recently classified as a variant of interest by the World Health Organization (WHO) based on its high circulation rates in South America, and has showed "the ability to escape from neutralizing antibodies elicited by CoronaVac."

Due to limited familiarity with providing antiretroviral medication, many participants were hesitant to initiate PrEP.

Associations found in people under the age of 45 were weaker in patients over that age.

Patients with a history of malnutrition had higher odds of developing severe disease.

Investigators wanted to study usage of F/TAF vs F/TDF in clinical practice and HIV seroconversion.

A new report, based on data from dialysis centers, suggests the US is far from reaching so-called “herd immunity.”

While a significantly reduced effectiveness was seen with 1 dose, only a small reduction was observed after 2.

Adherence for daily dosing decreased and event-driven PrEP usage increased in a Chinese study.

Impaired resilience was found to be associated with loneliness.

Virtual support services were crucial for providing continued care and education.

In a pilot project, customers were surveyed about HIV risk behaviors to gain further insights and assessed for potential PrEP utilization.

A research team working across several nursing homes sought to reduce antimicrobial use.

Many respondents reported having a lack of information about the use of PrEP.

PLWH should strictly maintain ART therapy and COVID-19 mitigation efforts.

Crowdsourcing and other approaches may develop more effective interventions to promote PS.

More tailored strategies could improve PrEP provision in family planning clinics.

A meta-analysis study found that 70% of PrEP users either stopped or had inadequate adherence within 6 months of initiation.